Intercellular adhesion molecule inhibitors as potential therapy for refractory uveitic macular edema

Jianmin Wang, Mohamed Ibrahim, Peykan Turkcuoglu, Elham Hatef, Afsheen Khwaja, Roomasa Channa, Diana V. Do, Quan Dong Nguyen

Research output: Contribution to journalArticle

13 Scopus citations

Abstract

Purpose: To describe the bioactivity of an intercellular adhesion molecule inhibitor (efalizumab) in a patient with refractory uveitic macular edema. Methods: A 55-year-old man presented with idiopathic autoimmune uveitis and associated macular edema, which could not be controlled by regional and systemic corticosteroid and selected immunomodulatory therapy. Efalizumab was administered as subcutaneous injections. Results: After 37 weekly injections of efalizumab, the uveitic macular edema was successfully eliminated. Six months following discontinuation of efalizumab, there were no signs of recurrent inflammation. Conclusion: Further investigation of the role of intercellular adhesion molecule inhibitors in the management of uveitic macular edema is indicated.

Original languageEnglish (US)
Pages (from-to)395-398
Number of pages4
JournalOcular Immunology and Inflammation
Volume18
Issue number5
DOIs
StatePublished - Oct 1 2010

Keywords

  • ICAM inhibitor
  • Macular edema
  • Uveitis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Ophthalmology

Fingerprint Dive into the research topics of 'Intercellular adhesion molecule inhibitors as potential therapy for refractory uveitic macular edema'. Together they form a unique fingerprint.

  • Cite this

    Wang, J., Ibrahim, M., Turkcuoglu, P., Hatef, E., Khwaja, A., Channa, R., Do, D. V., & Nguyen, Q. D. (2010). Intercellular adhesion molecule inhibitors as potential therapy for refractory uveitic macular edema. Ocular Immunology and Inflammation, 18(5), 395-398. https://doi.org/10.3109/09273948.2010.483317